The mammalian target of rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells

Canadian Journal of Cardiology

Volumn 30, Issue 5, 2014, Pages 568-575

  Zhan, Jun Kun ^a   Wang, Yan Jiao ^a   Wang, Yi ^a   Wang, Sha ^a   Tan, Pan ^a   Huang, Wu ^a   Liu, You Shuo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCEROL 2 PHOSPHATE; GLYCEROPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OSTEOCALCIN; RAPAMYCIN; SMALL INTERFERING RNA;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; MUSCLE CELL; OSTEOBLAST; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MUSCLE, SMOOTH, VASCULAR; OSTEOBLASTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR CALCIFICATION;

EID: 84899957532     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.11.005     Document Type: Article

References (37)

1. Nakano-Kurimoto R., Ikeda K., Uraoka M., et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol 2009, 297:H1673-H1684.
2. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol 2004, 15:2959-2964.
3. Ciceri P., Volpi E., Brenna I., et al. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrol Dial Transplant 2012, 27:122-127.
4. Zavaczki E., Jeney V., Agarwal A., et al. Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int 2011, 80:731-739.
5. Giachelli C.M., Speer M.Y., Li X., Rajachar R.M., Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 2005, 96:717-722.
6. Lauring J., Park B.H., Wolff A.C. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw 2013, 11:670-678.
7. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
8. Sun H., Kim J.K., Mortensen R.M., et al. Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling. Stem Cells 2013, 31:2183-2192.
9. Yeh L.C., Ma X., Ford J.J., Adamo M.L., Lee J.C. Rapamycin inhibits BMP-7-induced osteogenic and lipogenic marker expressions in fetal rat calvarial cells. J Cell Biochem 2013, 114:1760-1771.
10. Pantovic A., Krstic A., Janjetovic K., et al. Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells. Bone 2013, 52:524-531.
11. Tarantino G., Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med 2013, 45:348-356.
12. Caramés B., Hasegawa A., Taniguchi N., et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis 2012, 71:575-581.
13. Linford N.J., Beyer R.P., Gollahon K., et al. Transcriptional response to aging and caloric restriction in heart and adipose tissue. Aging Cell 2007, 6:673-688.
14. Grundmann S., Hans F.P., Kinniry S., et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation 2011, 123:999-1009.
15. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
16. Tato I., Bartrons R., Ventura F., Rosa J.L. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem 2011, 286:6128-6142.
17. Corradetti M.N., Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 2006, 25:6347-6360.
18. Marks A.R. Rapamycin: signaling in vascular smooth muscle. Transplant Proc 2003, 35:231S-233S.
19. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
20. Luo X.H., Zhao L.L., Yuan L.Q., et al. Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification. J Bone Miner Res 2009, 24:1461-1468.
21. Campbell J.H., Campbell G.R. Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci (Lond) 1993, 85:501-513.
22. Gregory C.A., Gunn W.G., Peister A., Prockop D.J. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 2004, 329:77-84.
23. Luo X.H., Guo L.J., Xie H., et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts via the MAPK signaling pathway. J Bone Miner Res 2006, 21:1648-1656.
24. Liang Q.H., Jiang Y., Zhu X., et al. Ghrelin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the ERK pathway. PLoS One 2012, 7:e33126.
25. Shan P.F., Lu Y., Cui R.R., et al. Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011, 6:e17938.
26. Li G.Z., Jiang W., Zhao J., et al. Ghrelin blunted vascular calcification in vivo and in vitro in rats. Regul Pept 2005, 129:167-176.
27. Abedin M., Tintut Y., Demer L.L. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004, 24:1161-1170.
28. Shioi A., Nishizawa Y., Jono S., et al. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995, 15:2003-2009.
29. Li J., Zhang B., Huang Z., et al. Taurine prevents beta-glycerophosphate-induced calcification in cultured rat vascular smooth muscle cells. Heart Vessels 2004, 19:125-131.
30. Dai Z.J., Gao J., Ma X.B., et al. Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci 2012, 14:273-285.
31. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001, 104:852-855.
32. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753.
33. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
34. Barb D., Neuwirth A., Mantzoros C.S., Balk S.P. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer 2007, 14:995-1005.
35. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
36. Cheng S.W., Fryer L.G., Carling D., Shepherd P.R. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. Biol Chem 2004, 279:15719-15722.
37. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.